Overview

Safety, Tolerability and Preliminary Efficacy of JK1201I in Patients With SCLC

Status:
Recruiting
Trial end date:
2023-03-31
Target enrollment:
Participant gender:
Summary
The purpose of this clinical trial is to evaluate the safety, tolerability and primary efficacy of JK-1201I in patients with small cell lung cancer (SCLC)
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
JenKem Technology Co., Ltd.
Collaborator:
Beijing Cancer Hospital
Treatments:
Irinotecan